About The Study: The amyloid probability score 2 (APS2) blood test and percentage of p-tau217 alone had high diagnostic accuracy for identifying Alzheimer disease among individuals with cognitive symptoms in primary and secondary care using predefined cutoff values. Future studies should evaluate how the use of blood tests for these biomarkers influences clinical care.
Corresponding Authors: To contact the corresponding authors, email Sebastian Palmqvist, M.D., Ph.D. (sebastian.palmqvist@med.lu.se) and Oskar Hansson, M.D., Ph.D. (oskar.hansson@med.lu.se).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.13855)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Alzheimer’s Association International Conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.13855?guestAccessKey=afaed68f-23d4-42cd-9123-49b9201851c6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072824
Journal
JAMA